New hope for lung cancer: targeted pill tested after other treatments fail

NCT ID NCT05297890

Ongoing Disease control Sponsor: CStone Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing the drug lorlatinib in about 70 Chinese patients with advanced ROS1-positive non-small cell lung cancer that has worsened after prior treatments (crizotinib and chemotherapy). The goal is to see how many patients respond to the drug and how long the response lasts. Lorlatinib is taken as a daily pill, and the study is open-label (everyone knows they are getting the drug).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Lorlatinib (a targeted cancer pill)

What this could lead to

If successful, lorlatinib could offer a new treatment option for people with ROS1-positive lung cancer whose disease has worsened after other therapies.

What could go wrong

This is a small, early-phase study (70 people) with no comparison group, so results may not apply broadly. Side effects from lorlatinib are possible, and the drug may not work for everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Locations

Beijing Cancer Hospital

Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences

Beijing, China
Chinese PLA Army Medical Center

Chongqing, China
Fudan University Shanghai Cancer Center

Shanghai, China
Fujian Cancer Hospital

Fuzhou, China
Guangdong Provincial People's hospital

Guangzhou, Guangdong, 510080, China
Harbin Medical University Cancer Hospital

Harbin, China
Henan Cancer Hospital

Zhengzhou, China
Henan Provincial People's Hospital

Zhengzhou, China
Hunan Cancer Hospital

Changsha, China
Jiangsu Province Hospital

Nanjing, China
Liaoning Cancer Hospital and Institute

Shenyang, China
Shandong Cancer Hospital&Institute

Jinan, China
Shanghai Pulmonary Hospital

Shanghai, China
Shanxi Cancer hospital

Taiyuan, China
Sichuan Cancer Hospital & Institute

Chengdu, China
Sun Yat-sen University Cancer Center

Guangzhou, China
Tangdu Hospital of The fourth Military Medical University Peoples Liberation Army of China

Xi'an, China
The 1st Affiliated hospital of Wenzhou Medical University

Wenzhou, China
The First Affiliated Hospital of Anhui Medical University

Hefei, China
The First Affiliated Hospital of Nanchang University

Nanchang, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, China
The First Hospital of Jilin University

Changchun, China
The Second Affiliated Hospital of Nanchang University

Nanchang, China
The first Affiliated hospital, Sun Yat-Sen University

Guangzhou, China
Tianjin Medical University Cancer Institute & Hospital

Tianjin, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, China
West China Hospital of Sichuan University

Chengdu, China
Xiamen Humanity Hospital

Xiamen, China
Yunnan Cancer Hospital

Kunming, China
Zhejiang Cancer Hospital

Hangzhou, China